Global Premier CRDMO: Enabling Global Partners and Delivering Sustainable High Growth

> 2023 Interim Results August 2023





Stock Code: 2269.HK

Forward-Looking Statements



This presentation may contain certain "forward-looking statements" which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, and our ability to protect our clients' intellectual property. Our forward-looking statements in this presentation speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section.

Use of Adjusted Financial Measures (Non-IFRS Measures)

We have provided adjusted net profit, adjusted net profit margin, adjusted EBITDA, adjusted EBITDA margin and adjusted diluted earnings per share for the corresponding periods, which excludes the share-based compensation expenses, listing expenses, gains or losses from equity investments and foreign exchange gains or losses, and are not required by, or presented in accordance with, IFRS. We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing underlying business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual and non-recurring items that we do not consider indicative of the performance of our business. However, the presentation of these non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies. CONTENTS









ESG as an Important Component of Business Strategy



Financial Overview





1H 2023 Interim Results 01



 $\begin{array}{c} \textbf{7.21} \xrightarrow{17.8\%} \textbf{8.49} \\ \hline \textbf{Revenue} (\textbf{RMB Bn}) \textbf{YoY} \end{array}$

 $\begin{array}{c} \textbf{2.91} \xrightarrow[]{0.4\%} \textbf{2.93} \\ \hline \textbf{Adj Net Profit (RMB Bn) YoY} \end{array}$

47.0% Adj Gross Profit Margin

34.5% Adj Net Profit Margin

45.0% Adj EBITDA Margin

0.65 Adj. Diluted EPS (RMB)



~60%

Non-COVID Projects Revenue Growth (YoY)

46 / 14 $\xrightarrow{57.1\%}$ **22**

New Projects Added / Commercial Projects YoY




Total Backlog (US\$ Bn) YoY

262KL Capacity in 1H 2023

12,397/4,344 Employees / Development Scientists

Financial Performance





6


Key Financials




AVAILABLE FUNDS	 Operating cash flow of RMB2.7 bn in 1H 2023 Available funds approx. RMB8.7 bn as of June 30, 2023 Total Liability to Equity Ratio 33.5%, expect to have sufficient funds for capacity expansion
САРЕХ	 1H 2023 CAPEX approx. RMB2.4 bn, mainly for capacity expansion in Europe, China and U.S. 2023 and 2024 CAPEX Plan: approx. RMB5 bn and RMB5-6 bn respectively each year from company's own funds
LOAN	 Approx. RMB2.8 bn borrowings as of June 30, 2023 Available bank credit facilities of around RMB6.5 bn
CASH FLOW	 2023 cash from operations target> RMB 6 bn Continued to target free cash flow positive in 2023

Post-IND Continued to Accelerate and Delivered Steady Revenue Growth






By Project Phase



- Early-phase revenue grew by 51.8% YoY thanks to seamless pre-IND development execution, demonstrating the successful implementation of "Follow the Molecule" strategy and indicating potential acceleration of late-phase and commercial manufacturing projects
- Due to biotech funding slowdown especially in China, pre-IND revenue increased by 6.6% YoY. With the biotech funding rebounding in U.S. and EU, revenue generated from pre-IND is expected to regain its momentum
- Late-phase and CMO revenue achieved steady growth: despite the declined revenue contribution from COVID, non-COVID revenue from late phase and CMO stage grew rapidly by 130.3% YoY

- Non-COVID projects delivered ~60% YoY revenue growth in 1H 2023, and will continue to fuel future growth
- COVID projects demonstrated the strength of the Group's technology platforms and speed of execution to win more projects from global clients

Non-COVID Projects Driving Growth with Strong Momentum



- 1H 2023: despite the headwinds from biotech funding slowdown, 44 non-COVID projects added in 1H 2023, maintain similar market share as before thanks to unique CRDMO business model, advanced R&D capabilities, strong execution, determined quality system and proven track record
- "Follow and Win the Molecule" for non-COVID projects will drive company's sustainable growth
- Thanks to our relentless efforts on COVID projects execution in past three years, we continued to win more trust from global clients and establish strong partnerships with them

Arcus Biosciences Expands Strategic Relationship with WuXi Biologics to Develop a Best-in-Class anti-CD39 Antibody for the Treatment of Cancer

- The parties will discover anti-CD39 antibodies using WuXi Bio's proprietary technology.
- This CD39 collaboration represents the fourth antibody development program on which the two companies have joined forces.
- Arcus was granted exclusive worldwide rights to anti-CD39 antibodies discovered under the collaboration and will be responsible for all further development and commercialization activities of such anti-CD39 antibodies.


WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers

- WuXi Biologics will provide an exclusive license to GSK for 1 preclinical bispecific T cell engaging (TCE) antibody and 3 additional bi-/multi-specific TCE antibodies developed using WuXi Biologics' proprietary technology platforms
- WuXi Biologics will receive an upfront payment of US\$40 million, up to ~US\$1.4 billion at key milestones and tiered royalties on net sales

WuXi Biologics

Moderate Growth in Pre-clinical Balanced with Strong Growth in Phase III & CMO, Deliver 2X Industry Growth

- Biotech funding slowdown especially in China resulted in softer growth in pre-clinical stage. Only observed 6Q into the cycle still highlighted our leadership position.
- Fewer projects additions but increased revenue per project thanks to more late stage and CMO projects. Sales cycle extension is the reason for the lower No. of projects
- "Win-the-Molecule" strategy continued to excel: 11 external projects transferred into the pipeline as of Jun 30, 2023, including 4 phase III projects and 2 CMO for blockbuster products
- 100+ client visits in 1H 2023. Already seen funding recovery from U.S. and EU market since June
- 22 CMO projects: total contract value of 4 new projects exceeding US\$1 bn



Notes: 1. As of lune


1. As of June 30, 2023

2. The commercial manufacturing projects refer to the projects approved by regulatory authorities and signed CMO contracts with the Group

WuXi Biologics

Backlog Underpins Future Performance

- Service Backlog
- Upcoming Potential Milestone Fees ⁽¹⁾
- Backlog within 3 Years



As of June 30, 2023, total backlog reached US\$20.1 bn. US\$13.6 bn service backlog as of June 30, 2023, "Win the Molecule" commercial projects brought over US\$1 bn backlog for mAb, bispecific and biosimilar projects, providing clear visibility of mid-to-long-term growth

Global Solution Provider

- Upcoming potential milestone backlog reached US\$6.5 bn, ~US\$60 mm milestone backlog converted to revenue in 1H 2023, still expect R to accelerate benefiting from technology enabling platforms and unique CRDMO business model
- As of June 30, 2023, backlog within 3 years approximated US\$3.5 bn, non-COVID backlog within 3 years increased by ~20% YoY, providing high visibility of strong short-term growth
- Excellent execution of pre-clinical projects and expanded capacity would shorten the order to fulfillment cycle


•

 Strong backlog does not indicate lack of capacity for new projects. Additional projects can be initiated within 4 weeks

Note:

- 1. Upcoming milestone revenue may take longer to receive at the various development stages as it depends on the success rate and progress of the projects
- 2. Results may not foot due to rounding

Rich Pipeline across All Biologics Modalities



222 First-in-class programs



21 vaccine projects, including 3 mRNA and 14 non-COVID vaccines



105 bispecific projects covering different formats

WuXi Biologics Global Solution Provi

110 Antibody Drug Conjugates (ADC)

projects with 44.7% YoY growth driven by increasing industry demands

17 CNS (Central Nervous System) programs from domestic and global companies with exciting potential




One of the largest portfolios of complex biologics, consisting of mAbs, bispecifics, multispecifics, ADCs, fusion proteins and vaccines, etc.

Notes:

1. As of June 30, 2023, compared with projects number as of June 30, 2022

2. Bispecific Antibody (BsAb) Included both WuXiBody® projects and non-WuXiBody® projects

New Projects Higher than Pre-COVID Solid Trend Continues



- The number of new projects reached peak in past 3 years due to COVID contribution and high-level biotech funding
- Despite the headwinds from biotech funding slowdown, our number of new projects is still much higher than pre-COVID, indicating more recognition and trust from the industry


"Win-the-Molecule" Strategy: Another Driver to Expand Pipeline and Deliver Additional Near-term Growth



"Win-the-Molecule" Projects

62 Total 62 projects at different stages (Phase I, II and III + CMO) transferred ٠ from global CDMOs or big pharmas to WuXi Biologics since 2018 **26** phase III & CMO projects drive significant near-term growth ۲ 51 Excellent execution, best timeline and leading technology underpin "Win-٠ the-Molecule" strategy 40 22 11 10 6 2018 2019 2020 2021 2022 1H 2023 Phase II Phase III &CMO Phase I Total





- Total contract value of four new projects exceeding US\$1 bn
- Reputation and strong brand recognition for "best in class" operational excellence. Proven technical capabilities, quality, reliability and industry leading timelines for projects, create a winning formula of trust and operational excellence and delivery for our clients

U.S. FDA Pre-license Inspection for AT-GAA Completed Follow the Molecule Strategy Validated Again



Amicus Therapeutics

Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates

May 10, 2023

1Q23 Revenue Growth of 14% at CER to \$86.3M

On Track to Deliver Full-Year 2023 Galafold Revenue Growth of 12%-17% at CER

U.S. FDA Pre-approval Inspection for AT-GAA Complete; Approval Expected 3Q 2023

European Launch of Pombiliti®+Opfolda® Expected 3Q 2023

Non-GAAP Profitability Projected in 2H 2023

Conference Call and Webcast Today at 8:30 a.m. ET

PHILADELPHIA, May 10, 2023 (GLOBE NEWSWIRE) -- <u>Amicus Therapeutics</u> (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the first quarter ended March 31, 2023.

Bradley Campbell, President and Chief Executive Officer of Amicus Therapeutics, Inc., stated, "We had an outstanding start to 2023 across our global business. In Q1, Galafold saw strong operational growth primarily driven by robust patient demand in our major markets. We are pleased with the outcome of the U.S. FDA inspection of the WuXi Biologics manufacturing facility and remain highly confident in the anticipated global approvals of AT-GAA as we move towards launch in the three largest Pompe markets this year. Our strategic focus remains on continuing to grow Galafold, securing regulatory approvals and launching of AT-GAA, and achieving non-GAAP profitability in the second half of 2023. Together, we see these driving value for our stakeholders and advancing our mission of delivering high quality medicines for people living with rare diseases."



- The U.S. FDA has completed the required pre-license inspection of Amicus's AT-GAA in 1H 2023
- Amicus continues to expect regulatory approval of AT-GAA in the U.S. in the 3Q 2023
- U.K. market authorization for AT-GAA in August 2023 and EU full approval in June 2023


Global Dual Sourcing Strategy Continues its Strong Momentum



Signed long-term agreement with Amicus further strengthens relationship and secures long-term capacity at our Ireland site

Commercial Manufacturing will Drive Strong Growth from 2021 and Beyond





- CMO projects expected to increase by implementing "Follow and Win the Molecule" strategies
- "Win-the-Molecule" enables WuXi Bio to secure more potential CMO projects

Robust Global Network to Enable Partners: Multiple Nodes with Geographic Diversity



Global CRDMO: 3 R centers + 8 D centers + 9 M centers

R: Shanghai WGQ, Shanghai FX, Boston

D: Shanghai WGQ, Wuxi, Shanghai FX, Chengdu, Hangzhou, Suzhou, Cranbury NJ and Singapore

M: Wuxi, Hebei, Chengdu, Hangzhou, Wuppertal, Leverkusen, Dundalk, Worcester MA and Singapore



New Chapter for Global Operations Development and Hiring in U.S.& EU on track, 7-8 DS PPQ Expected in 2024, Driving Robust Revenue Increase





- MFG6/7 GMP released in Q4 2022, and received first GMP Certificate from Ireland
- 7 CMO contracts signed and almost fully booked in 2025
- 3 eng run completed with 100% `success rate, will kick off 1st PPQ and 5 PPQ expected in 2024



- MFG19 (6x2,000L currently expanding to 12x2,000L)
- DP7 (liquid/lyo commercial facility, Germany/EMA certified): with an annual capacity of approximately ten million doses, is being expanded to include a second variable filling line

MFG19/DP7 in

Germany



- MFG18, the first clinical manufacturing facility in U.S., started GMP operations in mid 2022
- 100% manufacturing success rate
- Attracted 20+ new clients to WuXi Bio
- 2023 focus is site improvement to prepare for a strong growth in 2024

MFG18 in New Jersey,

U.S.



- Construction on track and completed weather tight , GMP operation targeted in 2025 with total capacity of 24,000L
- Another choice in the U.S. within WuXi Bio global network

MFG11 in

Massachusetts, U.S.



- Design on track and completed land purchase
- Entered into a strategic partnership with
 Pharmadule Morimatsu to provide modular
 factory for 2 of
 production assets
- Setting up a comprehensive CRDMO center in Singapore for global customers

MFG10 in Singapore

MFG6/7 in Dundalk, Ireland

Eli Lilly Applies Single Use Technology in its Ireland Site Another Demonstration for This Manufacturing Technology



Eli Lilly picks ABEC for single-use Ireland facility

by <u>Millie Nelson</u> Thursday, July 13, 2023 5:33 am

ABEC will deliver multiple Customer Single Run (CSR) single-use systems to Eli Lilly's manufacturing facility in Limerick, Ireland.

Eli Lilly announced plans to build a €400+ million (\$433 million) greenfield site in Limerick, Ireland <u>last year</u>. The firm then magnified the investment to around \$1 billion to further support its biologics ambition in the country . in March.

Now, Lilly has selected ABEC, a solutions and services for biotech manufacturing to support Basis of Design (BOD) engineering of the plant's upstream and downstream processes. ABEC will implement its single-use technology and its large-scale CSR bioreactors will be "at the heart of the facility," used for Lilly's high-density culture processes.





Big Pharma's Choice

Eli Lilly plans to expand its facility in Ireland with single use technology, showcasing the strength and trend of such manufacturing technology

WuXi Bio's Track Record



03

WuXi Bio delivered ~4 tons of COVID-19 neutralizing antibodies with single use technology, demonstrating that such technology is comparable to stainless steel in large-scale manufacturing

Single-Use in Capacity Expansion

Growing trend: 44% single-use technology is applied in new capacity; 36% single-use technology is applied in CMO capacity.



Ireland will Deliver High Revenue & Profitability




Signed Commercial Contracts		MFG	Scale (FB/L)	Est. Batches/Yr.
	Pharma A	Perfusion	1K	30+
	Pharma B	Fed Batch	12K	10+
•	Pharma C	Fed Batch	16K	6+
	Pharma D	Fed Batch	8K	20+
	Pharma E	Fed Batch	12K	15+
	Pharma F	Fed Batch	12K	13+
	Pharma G	Fed Batch	12K	20+



- Significant commercial manufacturing from 2024 onwards, almost fully booked in 2025
- 30% projects transferred from China as global dual sourcing ie follow the molecule
- 70% win the molecule for all potential blockbuster biologics, most of them for blockbuster products on the market

Sustained Growth with Diverse Engines





- North America: the biggest market with growth potential. Non-COVID revenue grew by 40.6% YoY and over 60% of new projects were added from this region in 1H 2023, expecting more growth drivers to fuel sustainable growth
- Europe: the market with the fastest growth rate. Non-COVID revenue grew by 238.9% YoY. Extended more collaboration with MNCs and biotech in EU and expect continued strong performance from EU market
- China: achieved 22.7% non-COVID revenue growth and collaborated more with high-quality clients, especially those who licensed out the products to global MNCs, partially offset by the impact from biotech funding constrains
- Rest of the World: continued to enable customers in this region and explored more collaborative opportunities

Excellent Operational Metrics




1H 2023 R&D Track Records	 Enabled 55 INDs in 1H 2023 and supported 440+ INDs as of June 30, 2023 Developed 40+ cell based assays in 1H 2023 and developed 340+ in total since 2017 Completed 130+ GMP audits/inspections in 1H 2023. 1,000+ audits/inspections completed since 2013 23 first-author publications in 1H 2023 with another 12+ already submitted Received EMA GMP certificate 9 months after facility release 11,900+ proteins generated to support global research in 1H 2023, which has already exceeded 2022 whole year total 1,000+ viral clearance projects completed since 2013
MFG Operational Excellence	 Drug Substance: 4 PPQ campaigns at 100% success rate in 1H 2023 and 2,500+ batches completed at 98%+ success rate overall Drug Product: 7 PPQ campaigns completed at 100% success rate in 1H 2023 and 1,700+ batches completed at 99%+ success rate overall, 100% mfg success for three years in a row 68 12000L batches completed at 100% success rate in 1H 2023 14 facilities with ~262,000L Drug Substance capacity in 1H 2023 vs 580,000L+ in the future 9 facilities for drug product filling, including 1 bioconjugate Drug Product by end of 1H 2023 Building 13 facilities globally


Bispecifics to be Another Growth Driver – WuXiBody®



Empower to discover best or first-in-class molecules








- WuXiBody[®] continues to gain worldwide recognition, with 42 out-licensed projects as of June 30, 2023
- 4 projects at Phase I, 5 projects at CMC, and 3 projects at PCC, demonstrating state-of-the-art technology of WuXiBody[®]
- 5 to 8 WuXiBody[®] projects are expected to get IND approval in 2024


Global Solution Provider

"Follow and Win the Molecule" Strategies Supporting Multiple XDCs













QUALITY is Our Competitive Advantage and Moat



1. As of June 30, 2023

Talent Forms the Prerequisite for Business Success



1. As of June 30, 2023, retention rate is calculated on voluntary staff turnover

WuXi Biologics

Benefits for WuXi Biologics from WuXi XDC's Proposed Spin-off Listing




Develop a Global Leading ADC and Bioconjugate CRDMO	 Enables WuXi XDC to develop a unique global leading CRDMO focusing on bioconjugate and capture opportunities in the fast- growing global ADC and bioconjugate market, with an independent fundraising platform Gives WuXi Biologics more flexibility and capacity to allocate capital among various businesses and drive long-term growth
More Defined and Delineated Business Focus and Strategy	 Business focus tailored to the respective drivers of profitability and long-term growth of WuXi Biologics More direct alignment of management's responsibilities and accountability in each company to improve efficiency
More Organized and Efficient Allocation of Capital and Resources	 Alleviates WuXi Biologics' capital demands to finance the ongoing CapEx plans of WuXi XDC at a fast-growing stage Enables WuXi Biologics to allocate resources effectively to biologics CRDMO business and improve capital utilization efficiency
Improved Governance, Market Communication and Transparency	 WuXi XDC's operational and financial performance (including capital commitment) are independently reported to investors Enhances market communication and enables investors to assess the value, performance and strategy of each of WuXi Biologics and WuXi XDC at different development stages more effectively
Value Creation for WuXi Biologics and Shareholders	 Fully develops and unlocks the intrinsic value of WuXi XDC with enhanced reputation and leadership position Maximizes the value creation for both WuXi Biologics and its shareholders as WuXi XDC will remain a subsidiary of the Company upon the Proposed Spin-off
No Material Adverse Financial Impact	 WuXi XDC remains as a subsidiary post spin-off, with financials continue to be consolidated into WuXi Biologics' statements No adverse impact on WuXi Biologics' financial and operational performance, as WuXi XDC's revenue and adjusted net profit accounted for ~6.5% and <5% of WuXi Biologics in 2022

WBS Drives **02** Operations Excellence


WuXi Biologics' Lean Operation and Management System





WBS Achievements in 1H 2023: On Target to Achieve Full Year Saving







- Drug Substance filter testing strategy harmonization
- On-time completion rate of Deviation increasing



- Buffer preparation process optimization
- Procurement strategy optimization
- Key reagent management optimization




- Payment process optimization, ↓ 11,000 hr/yr
- Standard work model for clinical QC establishment, ↓ 4,700 hr/yr



- ESG kaizen week
- Set up multi-tasks to improve ESG system

WuXi Biologics Global Solution Provider

WBS Drives Business Success



ESG as an Important Component of Business Strategy



ESG Highlights

- 1. 53% of employee are women; 47% of managerial positions and 30% of executive management are female
- 2. 100% renewable energy combined with disposable manufacturing technologies make Irish manufacturing site "greenest" biologics manufacturing globally
- 3. Committed to Science Based Targets Initiative (SBTi)
- 4. 21% YoY reduction in GHG emissions intensity (Scope 1/2)





Net-zero acience-based tarcets are lond-term targets that show companies how much they must reduce value chain emissions to align with reaching net-zero at the global or sector level in eligible 1.8°C pathways by 2050 or sconor. The SBT defines the state of net-zero emissions for companies Reaching a status of science-based net-zero emissions implies the following two conditions:

1H 2023 ESG Key Deliverables



Enhancing Governance

ESG Committee

Comprised of four board members Led by CEO

21 Material ESG issues

100%

Participation in business ethics and anti-corruption training

100% Supplier Code of Conduct Sign-Off

ISO27001

Information security certification

Enabling Clients and Community

573 Global partners *

621 Integrated projects*

agencies passed*

98%+

5,996

Inspections by global regulatory

Success rate of 2,500+ batches of

Volunteer hours for community

drug substance produced*

30

53% Female employees in STEM

47%

female

49 Nationalities represented by our employees

managerial positions are

Empowering

People

72 hours Of training per employee

ISO45001

Occupational health & safety certification

Greening Our Business

21% YoY reduction in GHG emissions intensity (Scope 1 and Scope 2)

5% YoY reduction of water intensity

New Waste Target


10% reduction of waste intensity by 2027 from base year of 2022

ISO14064 GHG emissions verification

ISO14001

Environment management certification

Integrated Strategy and Targets for Tackling Climate Change



WuXi Biologics

Climate Friendly Initiatives Across Global Sites





207 chargers for electric vehicles

ESG Performance Recognized as Industry Leader



WuXi Biologics

Financial Overview 04



47.0%

41.9%

34.5%

27.5%

2337.9

40.4%

36.4%

2621.2

+0.4%


2,914.9 2,925.6


1H 2022 1H 2023

Investment Impact

53.4%

Consistent Financial Growth Achieved





Gross Profit

37.7%

34.6%

41.8%

43.3%

37.1% 32.4% 39.3% 40.8% 40.2% 41.6% 45.1% 46.9% 44.0% 47.4% 6,724.0 RMB mm +4.3% GAGR: +64.8% 4.828.9 3,413.2 3,560.6 2,533.0 1.658.8 660.6 ^{1,017.8} 389.1 180.7 123.3 2016 2014 2015 2017 2018 2019 2020 2021 2022 1H 2022 1H 2023

44.1%

45.6%

48.8%

50.6%

33.4%

34.1%

3,435.9

.508.6

2021

33.1%

29.8%

5,053.9

1.234.

4.549

2022

50.0%

Notes:

RMB mm

98.6

2014

1. Adjusted EBITDA represents net profit before (i) interest expenses, income tax expenses, listing expenses (ii) certain non-cash expenses, consisting of share-based compensation, amortization and depreciation and (iii) foreign exchange gains/losses and (iv) fair value gains/losses on investment portfolios

2. Adjusted net profit excludes the share-based compensation expenses, fair value gains/losses on investment portfolios, foreign exchange gains/losses and listing expenses

Refers to foreign exchange gains/losses


2015


2016


4. Adjusted EBITDA and adjusted net profit of 2019 have been restated to further exclude the fair value gains/losses on the Group's investment portfolios




Sustained Profitability Over the Past 9 Years








Adjusted Diluted EPS⁽¹⁾



Note:

1. The authorized and issued shares of the Company were subdivided on the basis that every one (1) issued share is subdivided into three (3) subdivided shares (the "Share Subdivision"), which became effective on November 16, 2020. Basic and diluted earnings per share were stated after taking into account the effect of the Share Subdivision. Comparative figures have also been restated on the assumption that the Share Subdivision had been effective in the prior year


GP Margin: Industry Top-notch Position



Global Solution Provider



Free Cash Flow Positive in 2022 and 1H 2023




- Net operating cash flow recorded ~69%
 CAGR growth from 2017 to 2022
- RMB28+ bn CAPEX investment from 2017 to 2022 to support business growth
- Free cash flow turned positive in 2022 and continued to improve in 1H 2023: critical milestone for company growth
- Expect continued free cash flow positive in 2023 and beyond

Summary

05

Global Biologics CDMO Industry Continues to Grow




- MNCs are more willing to outsource rather than expand production capacity due to inflation
- The surging demands of AD drugs and the constraints of global biologics capacity further drive the growth of CDMO industry
- Multiple biologics are set to lose exclusivity in next few years, which may lead to the market expansion of biosimilar another tailwind for CDMO industry

WuXi Biologics

CRDMO: Three Growth Curves Drive Sustainable Long-term Growth



Three Long-Term Growth Curves



Proven CRDMO Business Model Continues to Deliver Sustainable Growth




Contract Services	Target Selection Reagent/Protein Generation & Assay Development Antibody Generation Complex Biologics Engineering (e.g., ADCs bsAb) Lead ID & Optimization Developability Assessment Characterization: (e.g., PK, PD, Efficacy, & Exploratory Tox PCC Selection Regulatory Support	 Cell Line Engineering Assay Development Process Development Drug Product Development DS & DP Scale Up Cell Banking & Characterization Pilot Scale Manufacturing Viral Clearance Late-stage Development & PC/PV IND & BLA Filing Support 	 DS GMP Manufacturing DP GMP Manufacturing QC Lot Release & Stability Global Dual Source Support One partner with expertise in all areas	
Requisites	State-of-the-art technology platforms enhance drug discovery capabilities	Best-in-class technology platforms, maximum scalability, speed and execution	Large CAPEX, validated quality and unwavering execution	
Current State	 Best mAb platform demonstrated by Arcus deal in 2018 Best bispecific platform demonstrated by GSK collaboration 	80+ new integrated projects per year	Explosive growth from 1 in 2019 to 17 in 2022 to 32+ expected in 2025	
Achievements	US\$6.5+ bn milestone backlog and 50+ programs with low single digit royalties	 ~US\$1 bn revenue per year from new projects only ~600 programs Rate: 95% Conversion R 	 Strongest growth potential benefiting from feed from R&D "Win-the-Molecule" expedites M 	

Growth Outlook

WuXi Biologics to continuously enable faster, better and cheaper services for biologics discovery, development and

manufacturing







D: already a strong global leader poised to grow as funding continue to improve. before and expect 80 new



Maintain similar market share as projects this year

Continue to invest in new technologies and platforms that drive future growth







1H 2023 Financial Summary

(RMB million)	1H 2023	1H 2022	Change
Revenue	8,492.0	7,206.4	17.8%
Cost of Sales	(4,931.4)	(3,793.2)	
Gross Profit	3,560.6	3,413.2	4.3%
Other Income	198.0	159.1	
Impairment Losses under ECL Model, Net of Reversal	(131.8)	(70.8)	
Other Gains and Losses	114.8	309.6	
Selling and Marketing Expenses	(105.4)	(67.1)	
Administrative Expenses	(679.6)	(520.1)	
Other Expenses	(7.4)	-	
Research and Development Expenses	(341.4)	(271.1)	
Financing Costs	(78.8)	(22.7)	
Profit before Tax	2,529.0	2,930.1	-13.7%
Income Tax Expenses	(191.1)	(308.9)	
Profit for the Period	2,337.9	2,621.2	-10.8%
Earnings per Share – Diluted (RMB)	0.52	0.58	
Adjusted Earnings per Share – Diluted (RMB)	0.65	0.65	

Notes: 1. Results may not foot due to rounding

Reconciliation for Adjusted Net Profit and Adjusted EBITDA



(RMB million)	1H 2023	1H 2022	Change
Adjusted Net Profit Reconciliation			
Net Profit	2,337.9	2,621.2	
Share-based Compensation Expense	632.4	568.6	
Foreign Exchange Gain	(107.5)	(94.0)	
Losses/(Gains) from Equity Investments	55.4	(180.9)	
Listing Expenses	7.4	-	
Adjusted Net Profit	2,925.6	2,914.9	0.4%
Adjusted EBITDA Reconciliation			
EBITDA	3,230.6	3,392.7	
Share-based Compensation Expense	632.4	568.6	
Foreign Exchange Gain	(107.5)	(94.0)	
Losses/(Gains) from Equity Investments	55.4	(180.9)	
Listing Expenses	7.4	-	
Adjusted EBITDA	3,818.3	3,686.4	3.6%

Notes:

1. Results may not foot due to rounding

WuXi Bio Vision

"Every drug can be made and every disease can be treated" by building an open-access platform with the most comprehensive capabilities and technologies in the global biologics industry

